ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
Promotion
Recombinantタンパク質s ClearClear history
Recombinantタンパク質s CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > EphA2

EphA2

概要

Name:Ephrin type-A receptor 2
Target Synonym:EC:2.7.10.1,Epithelial Cell Receptor Protein Tyrosine Kinase,Ephrin type-A receptor 2,Epithelial cell kinase,EPHA2,EPH Receptor A2,Tyrosine-Protein Kinase Receptor ECK,ECK,Soluble EPHA2 Variant 1,EC 2.7.10.1,CTRCT6,ARCC2,CTPP1,CTPA,Receptor, EphA2,EC 2.7.10
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

製品> フィルター結果
製品仕様別：
製品カテゴリー別：
種類別：
タグ別：
コンジュゲート：
製造番号 種類 製品説明 構造 純度 特徴
EP2-R52H5 Rat Rat EphA2 Protein, His Tag (MALS verified)
EP2-R52H5-structure
EP2-R52H5-sds
EP2-H82E4 Human Biotinylated Human EphA2 Protein, His,Avitag™ (MALS verified)
EP2-H82E4-structure
EP2-H82E4-sds
ACRO Quality

生物活性データの一部

EP2-H82E4-ELISA
EphA2 ELISA

Immobilized Biotinylated Human EphA2 Protein, His,Avitag (Cat. No. EP2-H82E4) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human Ephrin-A1, Fc Tag (Cat. No. EF1-H5251) with a linear range of 0.1-1 ng/mL (QC tested).

Protocol
EP2-R52H5-MALS-HPLC
EphA2 MALS images

The purity of Rat EphA2 Protein, His Tag (Cat. No. EP2-R52H5) is more than 90% and the molecular weight of this protein is around 50-65 kDa verified by SEC-MALS.

Synonym Name

EphA2

Background

Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Activated by the ligand ephrin-A1/EFNA1 regulates migration, integrin-mediated adhesion, proliferation and differentiation of cells. Regulates cell adhesion and differentiation through DSG1/desmoglein-1 and inhibition of the ERK1/ERK2 (MAPK3/MAPK1, respectively) signaling pathway. Engaged by the ligand ephrin-A5/EFNA5 may regulate lens fiber cells shape and interactions and be important for lens transparency development and maintenance. With ephrin-A2/EFNA2 may play a role in bone remodeling through regulation of osteoclastogenesis and osteoblastogenesis.

Clinical and Translational Updates

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Regorafenib DAST; BAY-73-4506 Approved Bayer AG Stivarga, Resihance United States Colorectal Neoplasms Bayer Healthcare Pharmaceuticals Inc 2012-09-27 Fallopian Tube Neoplasms; Osteosarcoma; Sarcoma, Ewing; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Peritoneal Neoplasms; Bone Neoplasms; Bile Duct Neoplasms; Thymoma; Thyroid Neoplasms; Leukemia, Myeloid, Acute; Gastrinoma; Lung Neoplasms; Esophageal adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Gastrointestinal Neoplasms; Somatostatinoma; Adenocarcinoma; Neoplasm Metastasis; Meningioma; Neoplasms; Solid tumours; Ovarian Neoplasms; Rectal Neoplasms; Carcinoma, Renal Cell; Hemangiosarcoma; Carcinoid Tumor; Insulinoma; Carcinoma, Islet Cell; Stomach Neoplasms; Esophageal Neoplasms; Liver Neoplasms; Carcinoma, Transitional Cell; Colonic Neoplasms; Pancreatic Neoplasms; Glioblastoma; Carcinoma, Ovarian Epithelial; Adenoma; Glucagonoma; Carcinoma, Adenoid Cystic; Sarcoma Details
Dasatinib Hydrate NSC-732517; BMS-354825; XS-004 Approved Bristol-Myers Squibb Company 施达赛, Dasynoc, Spricel, Sprycel, Spraysel United States Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic Bristol-Myers Squibb Company 2006-06-28 Primary Myelofibrosis; Hemangiopericytoma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Laryngeal Neoplasms; Lymphoma; Gliosarcoma; Peritoneal Neoplasms; Astrocytoma; Giant Cell Tumor of Bone; Gastrointestinal Stromal Tumors; Sarcoma, Alveolar Soft Part; Leukemia, Myeloid, Chronic-Phase; Sarcoma, Ewing; Lymphoma, Follicular; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Cholangiocarcinoma; Lymphoma, Mantle-Cell; Sarcoma; Neurofibrosarcoma; Breast Neoplasms; Brain Neoplasms; Melanoma; Leukemia, T-Cell; Carcinoma, Hepatocellular; Leukemia, Large Granular Lymphocytic; Adenocarcinoma; Mycosis Fungoides; Heart Arrest; Mastocytosis; Tongue Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Leukemia, Lymphocytic, Chronic, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Fallopian Tube Neoplasms; Lymphoma, T-Cell, Cutaneous; Uterine Neoplasms; Burkitt Lymphoma; Neoplasms, Gonadal Tissue; Intraocular Lymphoma; Lymphoma, Large-Cell, Anaplas Details
Regorafenib DAST; BAY-73-4506 Approved Bayer AG Stivarga, Resihance United States Colorectal Neoplasms Bayer Healthcare Pharmaceuticals Inc 2012-09-27 Fallopian Tube Neoplasms; Osteosarcoma; Sarcoma, Ewing; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Peritoneal Neoplasms; Bone Neoplasms; Bile Duct Neoplasms; Thymoma; Thyroid Neoplasms; Leukemia, Myeloid, Acute; Gastrinoma; Lung Neoplasms; Esophageal adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Gastrointestinal Neoplasms; Somatostatinoma; Adenocarcinoma; Neoplasm Metastasis; Meningioma; Neoplasms; Solid tumours; Ovarian Neoplasms; Rectal Neoplasms; Carcinoma, Renal Cell; Hemangiosarcoma; Carcinoid Tumor; Insulinoma; Carcinoma, Islet Cell; Stomach Neoplasms; Esophageal Neoplasms; Liver Neoplasms; Carcinoma, Transitional Cell; Colonic Neoplasms; Pancreatic Neoplasms; Glioblastoma; Carcinoma, Ovarian Epithelial; Adenoma; Glucagonoma; Carcinoma, Adenoid Cystic; Sarcoma Details
Dasatinib Hydrate NSC-732517; BMS-354825; XS-004 Approved Bristol-Myers Squibb Company 施达赛, Dasynoc, Spricel, Sprycel, Spraysel United States Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic Bristol-Myers Squibb Company 2006-06-28 Primary Myelofibrosis; Hemangiopericytoma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Laryngeal Neoplasms; Lymphoma; Gliosarcoma; Peritoneal Neoplasms; Astrocytoma; Giant Cell Tumor of Bone; Gastrointestinal Stromal Tumors; Sarcoma, Alveolar Soft Part; Leukemia, Myeloid, Chronic-Phase; Sarcoma, Ewing; Lymphoma, Follicular; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Cholangiocarcinoma; Lymphoma, Mantle-Cell; Sarcoma; Neurofibrosarcoma; Breast Neoplasms; Brain Neoplasms; Melanoma; Leukemia, T-Cell; Carcinoma, Hepatocellular; Leukemia, Large Granular Lymphocytic; Adenocarcinoma; Mycosis Fungoides; Heart Arrest; Mastocytosis; Tongue Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Leukemia, Lymphocytic, Chronic, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Fallopian Tube Neoplasms; Lymphoma, T-Cell, Cutaneous; Uterine Neoplasms; Burkitt Lymphoma; Neoplasms, Gonadal Tissue; Intraocular Lymphoma; Lymphoma, Large-Cell, Anaplas Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
BT-5528 BT-5528; BT5528 Phase 2 Clinical Bicycle Therapeutics Ovarian Neoplasms; Head and Neck Neoplasms; Carcinoma; Triple Negative Breast Neoplasms; Carcinoma, Non-Small-Cell Lung Details
siRNA-EphA2-DOPC Phase 1 Clinical The University Of Texas MD Anderson Cancer Center Solid tumours; Ovarian Neoplasms; Pancreatic Neoplasms Details
18F-Dasatinib 18F-SKI-249380; [18F]-Fluoro-BMS-354825; [18F]Dasatinib; [18F]SKI-249380; [18F]Fluoro-BMS-354825 Phase 1 Clinical Memorial Sloan Kettering Cancer Center Bone Marrow Neoplasms; Carcinoma; Neoplasms; Sarcoma; Diagnostic agents; Lymphoma; Melanoma Details
Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells therapy(California Institute For Regenerative Medicine) Phase 1 Clinical California Institute For Regenerative Medicine, National Cancer Institute Glioblastoma Details
BT-5528 BT-5528; BT5528 Phase 2 Clinical Bicycle Therapeutics Ovarian Neoplasms; Head and Neck Neoplasms; Carcinoma; Triple Negative Breast Neoplasms; Carcinoma, Non-Small-Cell Lung Details
siRNA-EphA2-DOPC Phase 1 Clinical The University Of Texas MD Anderson Cancer Center Solid tumours; Ovarian Neoplasms; Pancreatic Neoplasms Details
18F-Dasatinib 18F-SKI-249380; [18F]-Fluoro-BMS-354825; [18F]Dasatinib; [18F]SKI-249380; [18F]Fluoro-BMS-354825 Phase 1 Clinical Memorial Sloan Kettering Cancer Center Bone Marrow Neoplasms; Carcinoma; Neoplasms; Sarcoma; Diagnostic agents; Lymphoma; Melanoma Details
Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells therapy(California Institute For Regenerative Medicine) Phase 1 Clinical California Institute For Regenerative Medicine, National Cancer Institute Glioblastoma Details

This web search service is supported by Google Inc.

totopphone
Call us
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
日本：+(0)81-50-547-99099
Email
メールアドレス
order.jp@acrobiosystems.com
Fax
ファックス
+1 888-377-6111
Address
株式会社アクロバイオシステムズ
〒157-0066
東京都世田谷区成城1丁目26番9-101号

アクロバイオシステムズの公式アカウント

linkedin twitter facebook youtube

お問い合わせ（半角英文字で入力してください）

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap